Clinically, TPO-Abs have been associated with both an increased risk of BC (8,9,38) and a lower risk of BC; in some cases, TPO-Abs have even been associated with a lower frequency of distant metastases (39), a better outcome and better overall survival(27,38). This evidence concerns the gene TPO and breast cancer.